Protalix BioTherapeutics Inc (PLX)

0.82
0.00 0.48
AMEX : Health Care
Prev Close 0.83
Open 0.81
Day Low/High 0.80 / 0.82
52 Wk Low/High 0.61 / 1.78
Volume 713.72K
Avg Volume 1.64M
Exchange AMEX
Shares Outstanding 126.50M
Market Cap 104.99M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Protalix Cystic Fibrosis Drug Study Results Worsen Over Time

Protalix Cystic Fibrosis Drug Study Results Worsen Over Time

The Protalix medicine alidornase alfa is designed to help cystic fibrosis patients clear their lungs by making mucus thin and loose.

Protalix BioTherapeutics Announces Positive Results From Phase II Clinical Trial Of Alidornase Alfa (AIR DNase™) For The Treatment Of Cystic Fibrosis

Positive Results in a Number of Clinically Relevant Parameters Suggest Improved Lung Function with alidornase alfa

Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta

Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Protalix BioTherapeutics Receives Confirmation Of Order For Over $24 Million Of Alfataliglicerase To Treat Gaucher Patients In Brazil

Protalix BioTherapeutics Receives Confirmation Of Order For Over $24 Million Of Alfataliglicerase To Treat Gaucher Patients In Brazil

Shipment Size for Fourth Quarter of 2017 Represents Annual Revenues of approximately $42 Million

Alfataliglicerase Approved For Pediatric Indications In Brazil For The Treatment Of Gaucher Disease In Children Four Years And Older

Alfataliglicerase Approved For Pediatric Indications In Brazil For The Treatment Of Gaucher Disease In Children Four Years And Older

Approval further supports the advanced ongoing discussions with the Brazilian Ministry of Health for the supply of a significant amount of alfataliglicerase for Gaucher patients in Brazil

Protalix BioTherapeutics Doses First Patient In Global Phase III Clinical Trial Of PRX-102 For The Treatment Of Fabry Disease

Protalix BioTherapeutics Doses First Patient In Global Phase III Clinical Trial Of PRX-102 For The Treatment Of Fabry Disease

Six Sites Activated Across the United States and Europe with additional patients currently in the screening process for potential inclusion in trial